K. Borden

Oncology · 2013

A researcher in the Science corpus: 1 paper; trusts 5 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom K. Borden trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. J. Goldman
  2. Michael M. Gottesman
  3. I. Weinstein
  4. J. Melo

Papers from K. Borden's perspective

Ordered by how strongly the researchers K. Borden trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. (New England Journal of Medicine)
  2. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy (Nature)
  3. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (New England Journal of Medicine)
  4. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. (New England Journal of Medicine)
  5. Chronic myeloid leukemia--advances in biology and new approaches to treatment. (New England Journal of Medicine)
  6. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase (Nature)
  7. Hallmarks of cancer: the next generation. (Cell)
  8. Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction (Cell)
  9. Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy (Nature Clinical Practice Oncology)
  10. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. (New England Journal of Medicine)

Their papers